@grandslam... No. I actually followed up with a detailed, page by page critique of (& set of recommendations for) the corporate presentation -- which, IMHO, is not ready for prime time and needs to be removed from the web site until it's fixed. Certainly not ready for a dog & pony show with NYC investment banks. I don't know who they think they're kidding. They're good people with a great medical technology and a lot of promise, but their communication & marketing veneer are backwoods level. These are not "$300 Million Biotech IPO" quality materials. At this point I'm tempted to offer my services to them to vet all of their communications and get them to baseline professional quality. It's incredible to me that people with such a compelling story to tell don't take the time to tell it properly. I mean, just look at the photos of Musick & Evans. My lord, what are they thinking?
Anyway, no, I have not heard anything. I suspect that Evans is doing other things these days, having moved from CFO to Chairman, Perhaps he isn't looking at E-Mail as much. I should just call him. I hope they haven't been sold a bill of goods by the kid who they just named the new CFO, as if this kid is going to sell big time investment banks on a company like this using a presentation that is poorly organized, incoherent in places, and suffering from major typos. I'm still rooting for them, but I want a realistic path back to trading in a time frame measured in weeks and months, not years. And I can't see how that can be anything but an OTC listing, as they promised pre-Zamora when they were delisted. If they're going to start talking major IPO, I need to see a heck of a lot more than what they have put on the table.
AI
